Small molecules play essential roles in different areas of basic research and are often used to address important biological questions. The aim of our Small Molecule Screening Facility is to enable research groups to address biological questions by identifying and developing novel “biotool” compounds against targets. We can assist groups in developing primary and secondary assays for screening against our in-house compound library and guide them through the process of developing tool compounds for their specific target.
The facility is a joint collaboration between the DKFZ (German Cancer Research Center) and the EMBL (European Molecular Biology Laboratory) providing the infrastructure and expertise to open up small molecule development to research groups at both institutions. Located at the EMBL, it has recently taken up work with three DKFZ experts as members of the screening team. Head of the screening team is Dr. Joe Lewis from EMBL, who has extensive experience in drug development.
Members of the DKFZ are encouraged to apply for screening projects that will be evaluated by the members of the DKFZ steering committee (Dietrich Keppler, Lutz Gissmann, Peter Angel, and Jörg Hoheisel).
Services provided:
- development of assays for medium-throughput screening;
- small molecule screening with up to 50,000 compounds;
- assistance in the design of secondary specificity assays;
- help in compound characterization;
Contact and application:
Members of the DKFZ interested in a screening project may contact the DKFZ steering committee members for further information.
Expression of interest should be directed to the steering committee by providing essential information on the planned project according to the application form.